Experimental and clinical evaluation of two "Atromid-S" analogues in relation to their  differential modes of action.
D000818:Animals; D001835:Body Weight; D002087:Butyrates / Q000494:pharmacology*; D002992:Clofenapate / Q000494:pharmacology* / Q000627:therapeutic use; D002994:Clofibrate / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use; D003920:Diabetes Mellitus / Q000401:mortality; D005230:Fatty Acids, Nonesterified / Q000097:blood; D005340:Fibrinogen / Q000032:analysis; D006801:Humans; D006949:Hyperlipidemias / Q000188:drug therapy; D007700:Kinetics; D008099:Liver / Q000033:anatomy & histology / Q000187:drug effects; D008297:Male; D009929:Organ Size; D051381:Rats; D011956:Receptors, Cell Surface / Q000187:drug effects; D012709:Serum Albumin / Q000378:metabolism; D013045:Species Specificity; D013329:Structure-Activity Relationship; D013975:Thyroxine-Binding Proteins / Q000378:metabolism
D002087:Butyrates; D005230:Fatty Acids, Nonesterified; D011956:Receptors, Cell Surface; D012709:Serum Albumin; D013975:Thyroxine-Binding Proteins; D002992:Clofenapate; D005340:Fibrinogen; D002994:Clofibrate